Fig. 4

IFITM3 knockdown alleviates seizure severity and neuroinflammatory responses in PTZ-kindled mice. (A) Western blot analysis was conducted to assess the expression of IFITM3, verifying the knockdown efficiency of LV-sh-IFITM3 in BV2 cells treated with LPS (n = 3). (B) Severity of seizures was scored according to the Racine scale for the vehicle + LV-sh-NC, PTZ + LV-sh-NC, and PTZ + LV-sh-IFITM3 groups. No seizures were observed in the vehicle + LV-sh-NC group, yielding a score of 0 (n = 16). (C) Representative EEG traces recorded in vivo from each experimental group (n = 3). (D–I) mRNA levels of IFITM3, IL-1β, IL-6, TNF-α, IL-18, and ASC in mouse cortical tissue were determined by RT-qPCR (n = 16). (J,K) Protein levels of IFITM3, cleaved caspase-3, caspase-3, cleaved caspase9, caspase-9, BAX, and BCL2 were evaluated by western blotting in the cortex lysates (n = 3). Statistical analysis was conducted using two-way ANOVA followed by Bonferroni multiple comparison tests. Data are presented as mean ± standard deviation.